Attendee search 

Akrivis (www.akrivis.com) is a privately held biopharmaceutical company based in Cambridge, Massachusetts (USA) and committed to the early detection, diagnosis and treatment of serious and life-threatening diseases. Its patented Z-TECT™ technology platform is in essence a versatile, high payload, sequentially targeted carrier system that provides: (1) ultrasensitive in vitro detection; (2) high resolution in vivo imaging; and (3) efficient and specific, sequentially targeted delivery of high drug payloads to targeted biomarkers with improved efficacy and safety. Beyond targeted therapies and theranostics for oncology, Akrivis has a core focus on children’s health with on-going projects in pediatric oncology (neuroblastoma and ALL with reduced off-target toxicity) as well as Duchenne Muscular Dystrophy (DMD).

Bancroft is a leading provider of programs and supports for children and adults with autism, intellectual or developmental disabilities, and those in need of neurological rehabilitation. Our services include special education, vocational training and supported employment, structured day programs, campus and community living programs, short-term behavioral stabilization services for children, in-home and outpatient services.

A private, nonprofit organization, Bancroft was founded in Haddonfield, N.J., in 1883. Over the years, we have grown to become the fifth-largest private employer in Camden County. We currently serve more than 1,500 children and adults annually in settings throughout Camden, Burlington, Gloucester, Ocean, Middlesex and Salem counties in New Jersey, and in southeastern Pennsylvania and northern Delaware.

For 130 years, Bancroft has been making a difference in the lives of many. The organization is well known for helping people with disabilities achieve fulfilling lives while improving their function, activity and participation in society. Bancroft’s reputation for excellence is based on our commitment to providing a spectrum of individualized services, treating each person with respect and dignity, and providing services in an encouraging and supportive environment.

CYTOSIAL Biomedic is a pre-clinical medical device startup dedicated to applying its patented chitosan-based breakthrough technology and expertise to the development of medical devices for regenerative medicine and tissue engineering.

Masonic Medical Research Laboratory is a not-for-profit institute dedicated to improving the health and quality of life for all. The Laboratory's primary mission is to conduct high quality basic and clinical research aimed at generating knowledge and information necessary for development of medical cures and treatments of tomorrow. The Laboratory is also committed to providing education and training to basic scientists, clinical researchers and students who will perpetuate and extend the fight against disease.

The Laboratory's primary focus is on basic medical research in the fields of Experimental Cardiology, Cardiac Electrophysiology, Molecular Biology and Molecular Genetics.

We incorporate semiconductor, microelectronics, bio-electronic and drug-formulation innovations into a technology platform from which we are already prototyping products that leap forward with unprecedented safety, ease-of-use and efficiency. Our initial in-vitro results demonstrate an ability to improve transdermic drug delivery by 4 to 10x on a large range of molecules.

Targeted medical applications range from prevention of bedsores to controlled pain-relief and wound healing. Combined with advanced photo-dynamic therapy, we develop advanced solutions for dermatology. Our total addressable market is estimated to reach $7 billion by 2018.

Dermatology (psoriasis, atopic demartitis, labial herpes, acne, alopecia, ...) ; Pain relief (chronic pain, BTP, neuropathic and arthritic pain) ; Bedsores (bedsore prevention, bedsore detection , chronic wounds)

Security and Safety / Controlled Drug Delivery / Programmable-Remote bolus / Measure of compliance

OrthoCyte Corporation, a subsidiary of BioTime, Inc., is a biotechnology company developing cell-based therapies for bone and orthopedic soft tissue diseases and injuries. OrthoCyte has a vast library of proprietary normal human progenitor stem cells to skeletal tissues including, bone, articular cartilage, intervertebral disc, tendon, and ligament, all of which are in the preclinical phase of development.

Many surgical procedures of the spine require bone grafts to regenerate bone that has been removed or damaged due to disease or trauma. OncoCyte is focused on working toward improving patient outcomes in the spinal orthobiologics market which is currently estimated to be over $2 billion annually in the U.S., and is expected to reach $2.7 billion annually by 2020, according to GlobalData.

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.

Orphan Drugs, Rare Diseases, Genetic Disorders